Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
 
Search Article 
  
Advanced search 
  Users Online: 487 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
BRIEF COMMUNICATION
Year : 2014  |  Volume : 18  |  Issue : 3  |  Page : 425-427

A retrospective study on finding correlation of pioglitazone and incidences of bladder cancer in the Indian population


1 Dr. V. Seshiah Diabetes Research Institute, Dr. V. Balaji Care Centre, Chennai, Tamil Nadu, India
2 Cancer Research and Relief Trust, Chennai, Tamil Nadu, India
3 Madras Cancer Care Foundation, Chennai, Tamil Nadu, India

Correspondence Address:
V Balaji
Dr. V. Seshiah Diabetes Research Institute, Dr. V. Balaji Care Centre, Chennai - 603 209, Tamil Nadu
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2230-8210.131223

Rights and Permissions

Objectives: This retrospective cohort study analyzed the clinical data of cancer patients conducted in a cancer hospital, Chennai to assess the correlation (if any) between use of antidiabetic agents including pioglitazone and the incidence of bladder cancer. Materials and Methods: Totally, 5079 cancer patients' with and without diabetes were included and analyzed in this retrospective study. Results: A total of 1077 patient data were screened out of a total of 5079. A total of 20 patients were found to have bladder cancer. Out of 1077 patients, 31 were pioglitazone users on the drug for not less than 2 years. The remaining 1046 were on other drugs other than pioglitazone. It is observed that 1 out of 31 developed bladder cancer in the pioglitazone group 19 out of 1046 developed bladder cancer in the nonpioglitazone group. The result of the analysis indicates that there is no significant (P = 0.918) association between pioglitazone and bladder cancer. Conclusion: In this retrospective study, the number of diabetic patients on pioglitazone with bladder cancer was fewer than the diabetic patients on other medications with the disease. Further, no link could be established between any specific drug use and bladder cancer. Least number of patients with bladder cancer was on pioglitazone, suggesting that pioglitazone alone cannot be considered a cause for increased incidence of bladder cancer in diabetic patients.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1632    
    Printed18    
    Emailed0    
    PDF Downloaded477    
    Comments [Add]    
    Cited by others 17    

Recommend this journal